CLL patients with certain genetic markers are considered to be high risk and their options for treatment have historically been limited. CLL expert Dr. Jeff Sharman joins Patient Power to discuss emerging approaches to treating high-risk CLL currently being studied in clinical trials.
Sponsored through an educational grant from TG Therapeutics.
Get email alerts | http://www.patientpower.info/alerts
Advertisement Single Between Content
Advertisement Single Between Content
Advertisement Single Between Content
Subscribe on YouTube | http://www.youtube.com/patientpower
Like on Facebook | http://www.fb.com/patientpower.info
Follow on Twitter | http://www.twitter.com/patientpower
Follow on Google+ | http://www.google.com/+patientpowerinfo
Advertisement Single Below Content
Advertisement Single Below Content
Advertisement Single Below Content